Prof. Dr. RAMAZAN İDİLMAN

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , cilt.34, sa.2, ss.177-181, 2023 (SCI-Expanded)

47. Diagnosis and Treatment of Autoimmune Hepatitis: Questions, Answers, and Illustrative Cases: Endorsed by Autoimmune Liver Diseases Special Interest Group, Turkish Association for the Study of Liver

Özaslan E., Günşar F., ÇİFCİBAŞI ÖRMECİ A., Hatemi İ., Efe C., AKYOL G., et al.

Turkish Journal of Gastroenterology , cilt.34, 2023 (SCI-Expanded, Scopus, TRDizin)

48. The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort

Yaras S., Demir M., Barutcu S., Yildirim A. E., GÜREL S., Ucbilek E., et al.

Hepatology Forum , cilt.4, sa.3, ss.92-96, 2023 (Scopus)

49. Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome

Efe C., Kulkarni A. V., Terziroli Beretta-Piccoli B., Magro B., Stättermayer A., Cengiz M., et al.

Hepatology , cilt.76, sa.6, ss.1576-1586, 2022 (SCI-Expanded, Scopus)

50. Factors associated with the development of extrahepatic malignancy in patients with nonalcoholic fatty liver disease: a single-center longitudinal study

Gumussoy M., Koc O., KARATAŞ G., Ozercan M., Ellik Z., DUMAN S., et al.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.34, sa.11, ss.1172-1177, 2022 (SCI-Expanded, Scopus)

51. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

Efe C., Taşçılar K., Gerussi A., Bolis F., Lammert C., Ebik B., et al.

Journal of Autoimmunity , cilt.132, 2022 (SCI-Expanded, Scopus)

52. Liver fibrosis and its response to avapritinib in 2 patients with systemic mastocytosis

Cavazos K., Eswaran S., Maidlow C., KEKLİK KARADAĞ F., İDİLMAN R., İDİLMAN İ. S., et al.

BLOOD ADVANCES , cilt.6, sa.20, ss.5630-5633, 2022 (SCI-Expanded, Scopus)

53. Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants.

Ajmera V., Kim B. K., Yang K., Majzoub A. M., Nayfeh T., Tamaki N., et al.

Gastroenterology , cilt.163, sa.4, ss.1079, 2022 (SCI-Expanded, Scopus)

54. NATURAL DISEASE OUTCOMES IN PATIENT WITH NONALCOHOLIC FATTY LIVER DISEASE: A STUDY WITH PAIRED LIVER BIOPSIES

Gumussoy M., Gokce D., Ekelik M., KİREMİTCİ S., Bodakci E., DUMAN S., et al.

HEPATOLOGY , cilt.76, 2022 (SCI-Expanded, Scopus)

55. LOW SERUM ALBUMIN AT ADMISSION IS ASSOCIATED WITH MORTALITY AMONG INPATIENTS WITH CIRRHOSIS: A MULTI-NATIONAL EXPERIENCE

Wong F., Choudhury A. K., Xie Q., İDİLMAN R., George J., Kouacou M. J. D. L. E., et al.

HEPATOLOGY , cilt.76, 2022 (SCI-Expanded)

56. EFFECT OF PROGNOSTIC NONINVASIVE TESTS ON DISEASE OUTCOME OF ALCOHOL-RELATED LIVER DISEASE

Zengin B. A., Gumussoy M., Duman S., Bodakçi E., Güvenir S. T., Ellik Z., et al.

HEPATOLOGY , 2022 (SCI-Expanded, Scopus)

57. MEFIB AND MAST SCORES ASSESSMENT OF INCIDENT LIVER-RELATED OUTCOMES IN NONALCOHOLIC FATTY LIVER DISEASE: AN INDIVIDUAL PATIENT META-ANALYSIS

Noureddin N., Ajmera V., Bergstrom J., Huang D., Siddiqi H., Majzoub A., et al.

HEPATOLOGY , cilt.76, 2022 (SCI-Expanded, Scopus)

58. DIFFERENCES IN MORTALITY RATES IN INPATIENTS WITH CIRRHOSIS DEPENDS ON THE LOW, MIDDLE OR HIGH INCOME COUNTRY LOCATION: MULTI-NATIONAL CLEARED CONSORTIUM EXPERIENCE

Bajaj J. S., Wong F., Xie Q., Topazian M., Aldo T., İDİLMAN R., et al.

HEPATOLOGY , cilt.76, 2022 (SCI-Expanded)

59. FUNCTIONAL CURE WITH LONAFARNIB-BASED THERAPY IN CHRONIC HEPATITIS DELTA

Yurdaydin C., Yurdcu E., Gumussoy M., KESKİN O., Gencdal G., Akyildiz M., et al.

HEPATOLOGY , cilt.76, 2022 (SCI-Expanded, Scopus)

60. Eliminating Viral Hepatitis in Turkey: Achievements and Challenges

AKARCA U. S., BAYKAM N., GÜNER H. R., GÜNŞAR F., İDİLMAN R., Kaymakoglu S., et al.

VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL , cilt.28, sa.2, ss.14-21, 2022 (ESCI, TRDizin)

61. Characteristics of patients with hepatocellular carcinoma: A multicenter study

Guzelbulut F., KARAOĞULLARINDAN Ü., AKKIZ H., ALTINTAŞ E., DEMİRTAŞ C. Ö., Bahadir O., et al.

HEPATOLOGY FORUM , cilt.3, sa.3, ss.71-76, 2022 (ESCI, Scopus, TRDizin)

62. NSAID-associated drug-induced liver injury prior to and following liver transplantation

Gumussoy M., GÖKCAN H., BODAKÇİ E., KİREMİTCİ S., SAVAŞ B., İDİLMAN R.

HEPATOLOGY FORUM , cilt.3, sa.3, ss.108-109, 2022 (ESCI)

63. Liver stiffness on magnetic resonance elastography and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants

Ajmera V., Yang K., Kim B. K., Majzoub A., Tamaki N., Nakajima A., et al.

JOURNAL OF HEPATOLOGY , cilt.77, 2022 (SCI-Expanded)

64. Effectiveness of MRI methods in the assessment of hepatic steatosis in living liver donors

KURU ÖZ D., Ellik Z. M., Coruh A. G., ADIGÜZEL M., Gumussoy M., DUMAN S., et al.

JOURNAL OF HEPATOLOGY , cilt.77, 2022 (SCI-Expanded)

65. Chronic hepatitis delta with normal ALT and hepatitis D viremia

Arici S., Palom A., Gumussoy M., İDİLMAN R., Gencdal G., Esteban R., et al.

JOURNAL OF HEPATOLOGY , cilt.77, 2022 (SCI-Expanded)

66. The course of COVID-19 infection in patients with chronic hepatitis B and Delta

PARLAR Y. E., KESKİN O., KIRMIZIGÜL B., Gencdal G., Zeybel M., Gumussoy M., et al.

JOURNAL OF HEPATOLOGY , cilt.77, 2022 (SCI-Expanded, Scopus)

67. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis

Yurdaydin C., Keskin O., Yurdcu E., Caliskan A., Onem S., Karakaya F., et al.

HEPATOLOGY , cilt.75, sa.6, ss.1551-1565, 2022 (SCI-Expanded, Scopus)

68. Global multi-stakeholder endorsement of the MAFLD definition

Méndez-Sánchez N., Bugianesi E., Gish R. G., Lammert F., Tilg H., Nguyen M. H., et al.

LANCET GASTROENTEROLOGY & HEPATOLOGY , cilt.7, sa.5, ss.388-390, 2022 (SCI-Expanded, Scopus)

69. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

Efe C., Lammert C., Taşçılar K., Dhanasekaran R., Ebik B., Higuera-de la Tijera F., et al.

Liver International , cilt.42, sa.3, ss.607-614, 2022 (SCI-Expanded, Scopus)

70. An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B

Kim H. Y., Lampertico P., Nam J. Y., Lee H., Kim S. U., Sinn D. H., et al.

JOURNAL OF HEPATOLOGY , cilt.76, sa.2, ss.311-318, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

71. Evaluation of Magnetic Resonance Elastography and Transient Elastography for Liver Fibrosis and Steatosis Assessments in the Liver Transplant Setting

Ellik Z., İDİLMAN İ. S., Kartal A., Balaban Y., ELHAN A. H., KARÇAALTINCABA M., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.33, sa.2, ss.153-160, 2022 (SCI-Expanded, Scopus, TRDizin)

72. Advancing the global public health agenda for NAFLD: a consensus statement

Lazarus J. V., Mark H. E., Anstee Q. M., Arab J. P., Batterham R. L., Castera L., et al.

Nature Reviews Gastroenterology and Hepatology , cilt.19, sa.1, ss.60-78, 2022 (SCI-Expanded, SSCI, Scopus)

73. Characteristics of Newly Diagnosed Hepatocellular Carcinoma Patients Across Turkey: Prospective Multicenter Observational 3K Registry Study

AKARCA U. S., Unsal B., Sezgin O., Yalcin K., Akdogan M., Gonen C., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.32, sa.12, ss.1019-1028, 2021 (SCI-Expanded, Scopus, TRDizin)

74. Determination of Turkish norms of psychometric tests for diagnosing minimal hepatic encephalopathy and proposal of a high sensitive screening test battery

ÖZBAŞ B., Keskin O., Hecker H., Karahan I., ÖZBAŞ C., Kalkan C., et al.

HEPATOLOGY INTERNATIONAL , cilt.15, ss.1442-1455, 2021 (SCI-Expanded, Scopus)

75. HBV/HDV management after liver transplantation: Review

Muhammad H., Zaffar D., Tehreem A., Peng-Sheng T., ŞİMŞEK C., GÖKCAN H., et al.

Journal of Liver Transplantation , 2021 (Hakemli Dergi)

76. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B

Jang H., Yoon J. S., Park S. Y., Lee H. A., Jang M., Kim S. U., et al.

Clinical Gastroenterology and Hepatology , cilt.74, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

77. Recommendations for Hepatitis B Immunoglobulin and Antiviral Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation

AKARSU M., Onem S., TURAN İ., Adali G., Akdogan M., Akyildiz M., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.32, sa.9, ss.712-719, 2021 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

78. The feasibility of T2 mapping in the assessment of hepatic steatosis, inflammation, and fibrosis in patients with non-alcoholic fatty liver disease: a preliminary study.

Idilman I. S., Celik A., Savas B., Idilman R., Karcaaltincaba M.

Clinical radiology , cilt.76, sa.9, 2021 (SCI-Expanded, Scopus)

79. Etiology of Cirrhosis in Turkey: A National Cohort Study

YILDIRIM A. E., ÜÇBİLEK E., Oruncu M. B., TURAN İ., DEMİR M., Koksal A., et al.

JOURNAL OF HEPATOLOGY , cilt.75, 2021 (SCI-Expanded)

80. The artificial intelligence-driven model for prediction of hepatocellular carcinoma development in chronic hepatitis B patients: Derivation and validation using 11, 111 patients from Asian and Caucasian cohorts

Kim H. Y., Lampertico P., Nam J. Y., Lee H., Kim S. U., Jang E. S., et al.

JOURNAL OF HEPATOLOGY , cilt.75, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

81. Outcomes and characteristics of hepatocellular carcinomas (HCC) in Caucasian chronic hepatitis B (CHB) patients treated with long-term entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy

Papatheodoridis G., Dalekos G., İDİLMAN R., Sypsa V., Buti M., Calleja Panero J. L., et al.

JOURNAL OF HEPATOLOGY , cilt.75, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma

82. Association between non-alcoholic fatty liver disease and extrahepatic malignancy

Gumussoy M., İDİLMAN R., GÖKCAN H., Gokce D., Ulas B. B., Koc O., et al.

JOURNAL OF HEPATOLOGY , cilt.75, 2021 (SCI-Expanded)

83. Hepatitis D Infection in Asia: A Perspective From an Endemic Region

GÖKCAN H., İDİLMAN R.

Clinical Liver Disease , cilt.18, sa.1, ss.26-29, 2021 (Scopus) Sürdürülebilir Kalkınma

84. Covid-19 in Liver Transplant Recipients: A National Cohort

Kabacam G., TURAN İ., KIYICI M., Ellik Z., DOLU S., Dayangac M., et al.

JOURNAL OF HEPATOLOGY , cilt.75, 2021 (SCI-Expanded, Scopus)

85. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B

Papatheodoridis G., Dalekos G. N., İDİLMAN R., Sypsa V., Van Boemmel F., Buti M., et al.

JHEP REPORTS , cilt.3, sa.3, 2021 (ESCI, Scopus)

86. Natural History of Cirrhosis: Changing Trends in Etiology Over the Years

İDİLMAN R., Aydogan M., Oruncu M. B., Kartal A., ELHAN A. H., Ellik Z., et al.

DIGESTIVE DISEASES , cilt.39, sa.4, ss.358-365, 2021 (SCI-Expanded, Scopus)

87. Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study

Efe C., Dhanasekaran R., Lammert C., Ebik B., Higuera-de la Tijera F., Aloman C., et al.

HEPATOLOGY , cilt.73, sa.6, ss.2099-2109, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

88. Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study

Bremer B., Anastasiou O. E., Hardtke S., Caruntu F. A., Curescu M. G., YALÇIN K., et al.

LIVER INTERNATIONAL , cilt.41, sa.2, ss.295-299, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

89. The Prevalence of Metabolic Associated Fatty Liver Disease in The Turkish Population: A Multicenter Study

YILMAZ Y., YILMAZ N., ATEŞ F., KARAKAYA M. F., GÖKCAN H., KAYA E., et al.

Hepatology forum , cilt.2, sa.2, ss.37-42, 2021 (ESCI, Scopus)

90. Hepatitis D virus and liver transplantation: Indications and outcomes

Muhammad H., Tehreem A., Hammami M. B., Ting P., Idilman R., Gurakar A.

WORLD JOURNAL OF HEPATOLOGY , cilt.13, sa.3, ss.291-299, 2021 (ESCI, Scopus)

91. Clinical significance of concomitant extrahepatic autoimmune disease in patients with autoimmune liver disease

KARAKAYA M. F., USTA Ş., ÖZTÜRK Y., KALKAN Ç., MELEKOĞLU ELLİK Z., ELHAN A. H., et al.

Hepatology Forum , cilt.1, sa.2, ss.3-6, 2021 (ESCI)

92. Immunoglobulin light chain amyloidosis presenting as Budd-Chiari syndrome

Ozercan M., Eser I., KİREMİTCİ S., PEYNİRCİOĞLU B., Karayalcin S., İDİLMAN R.

Hepatology Forum , cilt.2, sa.3, ss.120-121, 2021 (Scopus)

93. ATA Index: A novel score for predicting fibrosis stage in chronic viral hepatitis

Tugsal H. Y., YÜKSEL S., Kabacam G., Evirgen S., Akan K., AKYÜZ F., et al.

HEPATOLOGY FORUM , sa.1, ss.12-19, 2021 (ESCI)

94. MRI quantification techniques in fatty liver: the diagnostic performance of hepatic T1, T2, and stiffness measurements in relation to the proton density fat fraction

Erden A., KURU ÖZ D., PEKER E., Kul M., Ates F. S. O., Erden I., et al.

DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY , cilt.27, sa.1, ss.7-14, 2021 (SCI-Expanded, Scopus, TRDizin)

95. Real-world efficacy and safety of Ledipasvir plus Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience

Degertekin B., DEMİR M., AKARCA U. S., Kani H. T., ÜÇBİLEK E., Yildirim E., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.31, sa.12, ss.883-893, 2020 (SCI-Expanded, Scopus, TRDizin)

96. Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta

Wranke A., Hardtke S., Heidrich B., Dalekos G., YALÇIN K., Tabak F., et al.

JOURNAL OF VIRAL HEPATITIS , cilt.27, sa.12, ss.1359-1368, 2020 (SCI-Expanded, Scopus)

97. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

Fan R., Papatheodoridis G., Sun J., Innes H., Toyoda H., Xie Q., et al.

JOURNAL OF HEPATOLOGY , cilt.73, sa.6, ss.1368-1378, 2020 (SCI-Expanded, Scopus)

98. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B

Papatheodoridis G., Dalekos G. N., İDİLMAN R., Sypsa V., Van Boemmel F., Buti M., et al.

JOURNAL OF HEPATOLOGY , cilt.73, sa.5, ss.1037-1045, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

99. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B

Papatheodoridis G. V., Sypsa V., Dalekos G. N., Yurdaydin C., Van Boemmel F., Buti M., et al.

JOURNAL OF HEPATOLOGY , cilt.72, sa.6, ss.1088-1096, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

100. The COVID-19 pandemic: Clinical practice advice for gastroenterologists, hepatologists, and liver transplant specialists

Kabacam G., Dayangac M., ÜÇBİLEK E., Ercin C. N., Gunsar F., Akyilchz M., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.31, sa.5, ss.348-355, 2020 (SCI-Expanded, Scopus, TRDizin)

101. A micro-elimination approach to addressing hepatitis C in Turkey

İDİLMAN R., Razavi H., Robbins-Scott S., AKARCA U. S., Ormeci N., Kaymakoglu S., et al.

BMC HEALTH SERVICES RESEARCH , cilt.20, sa.1, 2020 (SCI-Expanded, Scopus)

102. Metabolomics and microbial composition increase insight into the impact of dietary differences in cirrhosis

Cox I. J., İDİLMAN R., Fagan A., Turan D., Ajayi L., Le Guennec A. D., et al.

LIVER INTERNATIONAL , sa.2, ss.416-427, 2020 (SCI-Expanded, Scopus)

103. The natural course of non-alcoholic fatty liver disease

Cengiz Seval G., Kabaçam G., Yakut M., Seven G., Savaş B., Elhan A. H., et al.

Hepatology Forum , cilt.1, sa.1, ss.20-24, 2020 (ESCI, TRDizin)

104. The role of PNPLA3 (rs738409) cg variant on histological progression of non-alcoholic fatty liver disease

İDİLMAN R., ÖZEN KARATAYLI S. C., KABAÇAM G., SAVAŞ B., ELHAN A. H., BOZDAYI A. M.

Hepatology Forum , cilt.1, sa.3, ss.82-87, 2020 (ESCI, TRDizin)

105. A rare disease that presents with acute severe hepatitis: Kikuchi-Fujimoto disease

ÇALIŞKAN KARTAL A., İDİLMAN R., MELEKOĞLU ELLİK Z., SAĞLAM A., CİVRİZ BOZDAĞ S.

Hepatology forum , cilt.1, ss.41-42, 2020 (Scopus)

106. Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort

İDİLMAN R., DEMİR M., ALADAĞ M., Erol C., Cavus B., Iliaz R., et al.

JOURNAL OF VIRAL HEPATITIS , cilt.26, sa.6, ss.666-674, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

107. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial

Wedemeyer H., Yurdaydin C., Hardtke S., Caruntu F. A., Curescu M. G., YALÇIN K., et al.

LANCET INFECTIOUS DISEASES , cilt.19, sa.3, ss.275-286, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

108. Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib

Atilla P. A., Yalciner M., Atilla E., İDİLMAN R., BEKSAÇ M.

TURKISH JOURNAL OF HEMATOLOGY , cilt.36, sa.4, ss.266-273, 2019 (SCI-Expanded, Scopus, TRDizin)

109. Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up

van Campenhout M. J. H., Brouwer W. P., Xie Q., Guo S., Chi H., Qi X., et al.

JOURNAL OF VIRAL HEPATITIS , cilt.26, sa.1, ss.109-117, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

110. Health-related Quality of Life of Liver Donors: A Prospective Longitudinal Study

Hesimov I., Kirimker E. O., Duman B., Keskin O., ÇETİNKAYA Ö. A., Hayme S., et al.

TRANSPLANTATION PROCEEDINGS , cilt.50, sa.10, ss.3076-3081, 2018 (SCI-Expanded, Scopus)

111. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy

Lutterkort G. L., Wranke A., Hengst J., Yurdaydin C., Stift J., Bremer B., et al.

JOURNAL OF VIRAL HEPATITIS , cilt.25, sa.11, ss.1384-1394, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

112. Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort

Bajaj J. S., İDİLMAN R., Mabudian L., Hood M., Fagan A., Turan D., et al.

HEPATOLOGY , sa.1, ss.234-247, 2018 (SCI-Expanded, Scopus)

113. Serum biomarkers for the evaluation of liver fibrosis: The need for better tests

Zeybel M., İDİLMAN R.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.29, sa.4, ss.377-378, 2018 (SCI-Expanded, Scopus, TRDizin)

114. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population

Papatheodoridis G. V., Sypsa V., Dalekos G., Yurdaydin C., van Boemmel F., Buti M., et al.

JOURNAL OF HEPATOLOGY , cilt.68, sa.6, ss.1129-1136, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

115. Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease

Yurdaydin C., Keskin O., Kalkan C., Karakaya F., Caliskan A., Kabacam G., et al.

JOURNAL OF INFECTIOUS DISEASES , sa.8, ss.1184-1192, 2018 (SCI-Expanded, Scopus)

116. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study

Yurdaydin C., Keskin O., Kalkan C., Karakaya F., Caliskan A., Karatayli E., et al.

HEPATOLOGY , sa.4, ss.1224-1236, 2018 (SCI-Expanded, Scopus)

117. Turkey 2017 Clinical Practice Guidelines on recommendations for screning diagnosing and managing hepatitis C virus

Idilman R., Baykam N., KAYMAKOĞLU S., Tabak F., Bahcecioglu H. I., Bektas A., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, 2017 (SCI-Expanded, Scopus, TRDizin)

118. Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines

TABAK Ö. F., Yurdaydin C., KAYMAKOĞLU S., Tabak F., Akarsu M., Akinci E. G., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, 2017 (SCI-Expanded, Scopus, TRDizin)

119. Recommendation for treatment of hepatitis C virus infection

KAYMAKOĞLU S., Koksal I., KAYMAKOĞLU S., Tabak F., AKARCA U. S., Akbulut A., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, 2017 (SCI-Expanded, Scopus, TRDizin)

120. Diagnosis, management and treatment of hepatitis delta virus infection: Turkey 2017 Clinical Practice Guidelines

Yurdaydin C., Tabak F., KAYMAKOĞLU S., TABAK Ö. F., Akarsu M., Akinci E. G., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, 2017 (SCI-Expanded, Scopus, TRDizin)

121. Management of special patient groups with hepatitis B virus infection: The EASL 2017 Clinical Practice Guidelines

İDİLMAN R.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, sa.6, ss.518-521, 2017 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

122. The Risk of Hepatocellular Carcinoma Decreases After the First 5 Years of Entecavir or Tenofovir in Caucasians With Chronic Hepatitis B

Papatheodoridis G. V., İDİLMAN R., Dalekos G. N., Buti M., Chi H., van Boemmel F., et al.

HEPATOLOGY , cilt.66, sa.5, ss.1444-1453, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

123. The summarized of EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

İDİLMAN R.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, sa.5, ss.412-416, 2017 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

124. Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients With Chronic Hepatitis Delta Virus Infection

Canini L., Koh C., Cotler S. J., Uprichard S. L., Winters M. A., Han M. A. T., et al.

HEPATOLOGY COMMUNICATIONS , cilt.1, sa.4, ss.288-292, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

125. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study

Blach S., Zeuzem S., Manns M., Altraif I., Duberg A., Muljono D. H., et al.

The Lancet Gastroenterology and Hepatology , cilt.2, sa.3, ss.161-176, 2017 (SCI-Expanded)

126. Non-invasive fibrosis score for hepatitis delta

Lutterkort G. L., Wranke A., Yurdaydin C., Budde E., Westphal M., Lichtinghagen R., et al.

LIVER INTERNATIONAL , cilt.37, sa.2, ss.196-204, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

127. Daclatasvir Plus Asunaprevir Dual Therapy for Chronic HCV Genotype 1b Infection: Results of Turkish Early Access Program

Koklu S., Koksal I., AKARCA U. S., BALKAN A., Guner R., Demirezen A., et al.

ANNALS OF HEPATOLOGY , cilt.16, sa.1, ss.71-76, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

128. Discontinuation of lamivudine treatment in HBeAg-negative chronic hepatitis B: a pilot study with long-term follow-up

Karakaya F., Ozer S., Kalkan C., Tuzun E. A., Caliskan A., Keskin O., et al.

ANTIVIRAL THERAPY , sa.7, ss.559-570, 2017 (SCI-Expanded, Scopus)

129. Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B

Marcellin P., Ahn S. H., Chuang W. -., Hui A. J., TABAK Ö. F., Mehta R., et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.44, sa.9, ss.957-966, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

130. The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence

İDİLMAN R., Akyildiz M., Keskin O., Gungor G., Yilmaz T. U., Kalkan C., et al.

CLINICAL TRANSPLANTATION , cilt.30, sa.10, ss.1216-1221, 2016 (SCI-Expanded, Scopus)

131. Stone-containing Cystic Mass at the Portal Hilus of the Liver in an Asymptomatic Young Female Patient Duplication of the Gallbladder

İDİLMAN R., Erden A., Karakaya F.

GASTROENTEROLOGY , sa.2, 2016 (SCI-Expanded)

132. Comparison of survival, safety, and efficacy after transarterial chemoembolization and radioembolization of Barcelona Clinic Liver Cancer stage B-C hepatocellular cancer patients

SOYDAL Ç., Arslan M. F., KÜÇÜK N. Ö., İDİLMAN R., Bilgic S.

NUCLEAR MEDICINE COMMUNICATIONS , cilt.37, sa.6, ss.646-649, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

133. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy

Papatheodoridis G., Dalekos G., Sypsa V., Yurdaydin C., Buti M., Goulis J., et al.

JOURNAL OF HEPATOLOGY , cilt.64, sa.4, ss.800-806, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

134. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease

İDİLMAN İ. S., Keskin O., Celik A., SAVAŞ B., ELHAN A. H., İDİLMAN R., et al.

ACTA RADIOLOGICA , cilt.57, sa.3, ss.271-278, 2016 (SCI-Expanded, Scopus)

135. Latest updates on chronic viral hepatitis B

İDİLMAN R., Karakaya F.

MARMARA MEDICAL JOURNAL , cilt.29, ss.33-37, 2016 (ESCI)

136. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome

Keskin O., Wedemeyer H., Tuzun A., Zachou K., Deda X., Dalekos G. N., et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY , cilt.13, sa.13, ss.2342-2351, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

137. Sequential development of acute autoimmune hepatitis may lead to a serious clinical picture in primary biliary cirrhosis

Keskin O., İDİLMAN R.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.27, sa.10, ss.1228-1229, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

138. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial

Koh C., Canini L., Dahari H., Zhao X., Uprichard S. L., Haynes-Williams V., et al.

LANCET INFECTIOUS DISEASES , cilt.15, sa.10, ss.1167-1174, 2015 (SCI-Expanded, Scopus)

139. Therapy of Delta Hepatitis

Yurdaydin C., İDİLMAN R.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE , cilt.5, sa.10, 2015 (SCI-Expanded, Scopus)

140. Quantification of liver, pancreas, kidney, and vertebral body MRI-PDFF in non-alcoholic fatty liver disease

İdilman İ. S., Tüzün A. E., Savaş B., Elhan A. H., Çelik A., İdilman R., et al.

ABDOMINAL IMAGING , cilt.40, sa.6, ss.1512-1519, 2015 (SCI-Expanded)

141. Quantification of liver, pancreas, kidney, and vertebral body MRI-PDFF in non-alcoholic fatty liver disease

İDİLMAN İ. S., Tuzun A., SAVAŞ B., ELHAN A. H., Celik A., İDİLMAN R., et al.

ABDOMINAL IMAGING , cilt.40, sa.6, ss.1512-1519, 2015 (SCI-Expanded, Scopus)

142. Prognostic factors for prediction of survival of hepatocellular cancer patients after selective internal radiation therapy

SOYDAL Ç., Keskin O., KÜÇÜK N. Ö., ÖZKAN E., Bilgic S., İDİLMAN R., et al.

ANNALS OF NUCLEAR MEDICINE , cilt.29, sa.5, ss.426-430, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

143. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naive chronic hepatitis B patients in the real-world setting

Idilman R., Gunsar F., Koruk M., Keskin O., Meral C. E., Gulsen M., et al.

JOURNAL OF VIRAL HEPATITIS , cilt.22, sa.5, ss.504-510, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

144. Adding Pegylated Interferon to Entecavir for Hepatitis B e Antigen-Positive Chronic Hepatitis B: A Multicenter Randomized Trial (ARES Study)

Brouwer W. P., Xie Q., Sonneveld M. J., Zhang N., Zhang Q., TABAK Ö. F., et al.

HEPATOLOGY , cilt.61, sa.5, ss.1512-1522, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

145. Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B

Karatayli S. C., Bozdayi M., Karatayli E., ÖZTÜRK T., Husseini A. A., ALBAYRAK DELİALİOĞLU R., et al.

LIVER INTERNATIONAL , cilt.35, sa.3, ss.846-853, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

146. Nonalcoholic fatty liver disease is associated with significant coronary artery disease in type 2 diabetic patients: A computed tomography angiography study

İdilman R., Akata D., Hazırolan T., Doğanay B., Aytemir K., Karçaaltıncaba M.

JOURNAL OF DIABETES , cilt.7, sa.2, ss.279-286, 2015 (SCI-Expanded)

147. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir

Papatheodoridis G. V., Dalekos G. N., Yurdaydin C., Buti M., Goulis J., Arends P., et al.

JOURNAL OF HEPATOLOGY , cilt.62, sa.2, ss.363-370, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

148. A potential link between endothelial function, cardiovascular risk, and metabolic syndrome in patients with Non-alcoholic fatty liver disease

Arslan M. S., Turhan S., Dinçer İ., Mizrak D., Çorapçıoğlu D., İdilman R.

DIABETOLOGY & METABOLIC SYNDROME , cilt.6, 2014 (SCI-Expanded, Scopus)

149. Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta

Kabacam G., Wedemeyer H., SAVAŞ B., Keskin O., Dalekos G., TABAK Ö. F., et al.

LIVER INTERNATIONAL , cilt.34, sa.8, ss.1207-1215, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

150. Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade: Performance of phylogenetic analysis of the NS5B, E1, and 5 ' UTR regions in genotyping efficiency

Alagoz G. K., Karatayli S. C., Karatayli E., Celik E., Keskin O., Dinc B., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.25, sa.4, ss.405-410, 2014 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

151. Public awareness of hepatitis B infection in Turkey as a model of universal effectiveness in health care policy

Gurakar M., Malik M., Keskin O., İDİLMAN R.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.25, sa.3, ss.304-308, 2014 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

152. Historical epidemiology of hepatitis C virus (HCV) in selected countries

Bruggmann P., Berg T., Ovrehus A. L. H., Moreno C., Brandao Mello C. E., Roudot-Thoraval F., et al.

JOURNAL OF VIRAL HEPATITIS , cilt.21, ss.5-33, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

153. Strategies to manage hepatitis C virus (HCV) disease burden

Wedemeyer H., Duberg A. S., Buti M., Rosenberg W. M., Frankova S., Esmat G., et al.

JOURNAL OF VIRAL HEPATITIS , cilt.21, ss.60-89, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

154. A one step real time PCR method for the quantification of hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal control

Karatayli E., Altunoglu Y. C., Karatayli S. C., Alagoz S. G. K., ÇINAR K., YALÇIN K., et al.

JOURNAL OF CLINICAL VIROLOGY , cilt.60, sa.1, ss.11-15, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

155. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Razavi H., Waked I., Sarrazin C., Myers R. P., Idilman R., Calinas F., et al.

JOURNAL OF VIRAL HEPATITIS , cilt.21, ss.34-59, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

156. Impact of sequential proton density fat fraction for quantification of hepatic steatosis in nonalcoholic fatty liver disease

Idilman I. S., Keskin O., ELHAN A. H., Idilman R., KARÇAALTINCABA M.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.49, sa.5, ss.617-624, 2014 (SCI-Expanded, Scopus)

157. Tumour necrosis factor-alpha, interleukin-10, interferon-gamma and vitamin D receptor gene polymorphisms in patients with chronic hepatitis delta

Karatayli S. C., Ulger Z. E., Ergul A. A., Keskin O., Karatayli E., Albayrak R., et al.

JOURNAL OF VIRAL HEPATITIS , cilt.21, sa.4, ss.297-304, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

158. Endoscopic treatment of biliary complications following liver transplantation

Seven G., ÇINAR K., İDİLMAN R., TÜZÜNER A., Hazinedaroglu S. M., Karayalcin S., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.25, sa.2, ss.156-161, 2014 (SCI-Expanded, Scopus, TRDizin)

159. Manometric assessment of esophageal motor function in patients with primary biliary cirrhosis

Bektas M., Seven G., İDİLMAN R., Yakut M., DOĞANAY ERDOĞAN B., Kabacam G., et al.

EUROPEAN JOURNAL OF INTERNAL MEDICINE , cilt.25, sa.3, ss.230-234, 2014 (SCI-Expanded, Scopus)

160. Efficacy of tenofovir in adefovir-experienced patients compared with treatment-naive patients with chronic hepatitis B

Keskin O., Ormeci A. C., Baran B., Kabacam G., Tuzun A., Karatayli E., et al.

ANTIVIRAL THERAPY , cilt.19, sa.6, ss.543-550, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

161. Vanishing bile duct syndrome after allogeneic bone marrow transplantation: Is it the end of the road?

Bakanay S. M., Ugur Bilgin A., Bektas M., İDİLMAN R., Erden E., Arat M., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.24, sa.4, ss.359-362, 2013 (SCI-Expanded, Scopus, TRDizin)

162. Hepatic Steatosis: Quantification by Proton Density Fat Fraction with MR Imaging versus Liver Biopsy

İDİLMAN İ. S., Aniktar H., İDİLMAN R., Kabacam G., SAVAŞ B., ELHAN A. H., et al.

RADIOLOGY , cilt.267, sa.3, ss.767-775, 2013 (SCI-Expanded, Scopus)

163. Kidney transplantation from hepatitis B (HB)-positive donors to HB negative recipients: anti-HB Core immunoglobulin G became positive in all recipients after the transplantation.

Celebi Z. K., Sengul Ş., Soypacaci Z., Yayar O., Idilman R., Tuzuner A., et al.

Transplantation proceedings , cilt.45, sa.3, ss.923-5, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

164. Clonal analysis of the quasispecies of antiviralresistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir

Karatayli E., İDİLMAN R., Karatayli S. C., Cevik E., Yakut M., Seven G., et al.

Antiviral Therapy , cilt.18, sa.1, ss.77-85, 2013 (SCI-Expanded)

165. Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interactions

Nishimura T., Hu Y., Wu M., Pham E., Suemizu H., Elazar M., et al.

Journal of Pharmacology and Experimental Therapeutics , cilt.344, sa.2, ss.388-396, 2013 (SCI-Expanded)

166. The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country

Toy M., ÖNDER F. O., İDİLMAN R., Kabacam G., Richardus J. H., Bozdayi M., et al.

EUROPEAN JOURNAL OF HEALTH ECONOMICS , cilt.13, sa.5, ss.663-676, 2012 (SSCI, Scopus)

167. HBeAg-positive hepatitis delta: Virological patterns and clinical long-term outcome

Heidrich B., C. Serrano B., İDİLMAN R., Kabaçam G., Bremer B., Raupach R., et al.

Liver International , cilt.32, sa.9, ss.1415-1425, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

168. Entecavir treatment of chronic hepatitis D

Kabaçam G., Önder F. O., Yakut M., Seven G., Karatayli S. C., Karatayli E., et al.

Clinical Infectious Diseases , cilt.55, sa.5, ss.645-650, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

169. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients

Idilman R., Cinar K., Seven G., Bozkus Y., ELHAN A. H., Bozdayi M., et al.

JOURNAL OF VIRAL HEPATITIS , cilt.19, sa.3, ss.220-226, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

170. Potential proteomic biomarkers in assessing liver fibrosis using SELDI-TOF MS

Karatayli S. C., Alagöz S. G., Mizrak D., Sayki M., Özkan M., SAVAŞ B., et al.

Turkish Journal of Gastroenterology , cilt.23, sa.1, ss.46-53, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

171. Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection

Karatayli E., Karatayli S. C., ÇINAR K., GÖKAHMETOĞLU S., GÜVEN K., İDİLMAN R., et al.

Journal of Clinical Virology , cilt.53, sa.2, ss.130-134, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma

172. Hepatic encephalopathy

Yurdaydin C., İDİLMAN R.

European Gastroenterology and Hepatology Review , cilt.7, sa.4, ss.268-271, 2012 (Scopus)

173. Assessment of Helicobacter pylori eradication rate of triple combination therapy containing levofloxacin

Seven G., ÇINAR K., Yakut M., İDİLMAN R., Özden A.

Turkish Journal of Gastroenterology , cilt.22, sa.6, ss.582-586, 2011 (SCI-Expanded)

174. Complete genome sequences and phylogenetic analysis of hepatitis delta viruses isolated from nine Turkish patients

Çelik I., Karatayli E., Çevik E., Gökçe Kabakçi S., Karatayli S. C., Dinç B., et al.

Archives of Virology , cilt.156, sa.12, ss.2215-2220, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

175. Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: Before and after transplantation

İDİLMAN R., Arat M.

Expert Review of Anti-Infective Therapy , cilt.9, sa.8, ss.641-652, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

176. Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C

Çoban Ş., İDİLMAN R., Erden E., Tuz̈un̈ A.

Hepato-Gastroenterology , cilt.58, sa.109, ss.1301-1306, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma

177. Lymphoproliferative Disorders in Individuals With Chronic Hepatitis B and C in the Turkish Population

İDİLMAN R., Bozkus Y., CENGİZ SEVAL G., Mizrak D., ÇINAR K., Ustun Y., et al.

JOURNAL OF MEDICAL VIROLOGY , cilt.83, sa.6, ss.974-980, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

178. Natural history and treatment of chronic delta hepatitis.

Yurdaydin C., Idilman R., Bozkaya H., Bozdayi A.

Journal of viral hepatitis , cilt.17, sa.11, ss.749-56, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

179. MR angiography of esophageal mural veins in portal hypertension: a correlation with endoscopic grades of esophageal varices.

Erden A., İDİLMAN R., Erden I., Bektaş M., Özden A.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , cilt.21, sa.3, ss.275-9, 2010 (SCI-Expanded, Scopus, TRDizin)

180. The Characteristics and Clinical Outcome of Drug-induced Liver Injury A Single-center Experience

İDİLMAN R., Bektas M., Cinar K., TÖRÜNER M., Cerit E. T., DOĞANAY ERDOĞAN B., et al.

JOURNAL OF CLINICAL GASTROENTEROLOGY , cilt.44, sa.6, 2010 (SCI-Expanded, Scopus)

181. Endoscopic management of biliary parasitic diseases

Bektaş M., Dökmeci A., ÇINAR K., Halici I., Oztas E., Karayalcin S., et al.

Digestive Diseases and Sciences , cilt.55, sa.5, ss.1472-1478, 2010 (SCI-Expanded)

182. Gastric aberrant pancreas

Mizrak D., Bektaş M., KAYGUSUZ G., ÇINAR K., İDİLMAN R., Özden A.

Turkish Journal of Gastroenterology , cilt.21, sa.1, ss.68-69, 2010 (SCI-Expanded)

183. Aflatoxin exposure in viral hepatitis patients in Turkey

Mizrak D., Engin B., ÖNDER F. O., Yener B., Bektas M., Biyikli Z., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.20, sa.3, ss.192-197, 2009 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

184. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients

İDİLMAN R., Kaymakoglu S., Oguz Onder F., Ahishali E., Bektas M., ÇINAR K., et al.

Journal of Viral Hepatitis , cilt.16, sa.4, ss.279-285, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma

185. Awareness of the endoscopist affects detection rate of heterotopic gastric mucosa in esophagus

Korkut E., Bektas M., SAVAŞ B., Memmedzade F., Öztas E., Üstün Y., et al.

Indian Journal of Gastroenterology , cilt.28, sa.2, ss.75-76, 2009 (Scopus)

186. Veins around the esophagus and the stomach: Do their calibrations provide a diagnostic clue for portal hypertensive gastropathy?

Erden A., İDİLMAN R., Erden I., Ozden A.

CLINICAL IMAGING , cilt.33, sa.1, ss.22-24, 2009 (SCI-Expanded, Scopus)

187. PPAR-alpha L162V polymorphism in human hepatocellular carcinoma

Koytak E. S., Mizrak D., Bektas M., Verdi H., ARSLAN ERGÜL A., Idilman R., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.19, sa.4, ss.245-249, 2008 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

188. Hepatic complications of allogeneic hematopoietic cell transplantation

İDİLMAN R., Arat M.

Turkish Journal of Hematology , cilt.25, sa.3, ss.111-123, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma

189. Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis

Idilman R., Mizrak D., Corapcioglu D., Bektas M., Doganay B., Sayki M., et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.28, sa.2, ss.200-208, 2008 (SCI-Expanded, Scopus)

190. Adjuvant therapeutic plasma exchange in liver failure - Assessments of clinical and laboratory parameters

Bektas M., İDİLMAN R., Soykan I., Soydan E., Arat M., ÇINAR K., et al.

JOURNAL OF CLINICAL GASTROENTEROLOGY , cilt.42, sa.5, ss.517-521, 2008 (SCI-Expanded, Scopus)

191. P wave dispersion is prolonged in patients with Wilson's disease

Arat N., Kacar S., Golbasi Z., Akdogan M., Sokmen Y., Kuran S., et al.

WORLD JOURNAL OF GASTROENTEROLOGY , cilt.14, sa.8, ss.1252-1256, 2008 (SCI-Expanded, Scopus)

192. Hydatid cysts in muscle: a modified percutaneous treatment approach

Ormeci N., Idilman R., Akyar S., Palabiylkoglu M., Coban S., Erdem H., et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES , cilt.11, sa.3, ss.204-208, 2007 (SCI-Expanded, Scopus)

193. The fate of recipient-derived hepatocytes in sex-mismatched liver allograft following liver transplantation

Idilman R., Erden E., KUZU I., Ersoz S., Karayalcin S.

CLINICAL TRANSPLANTATION , cilt.21, sa.2, ss.202-206, 2007 (SCI-Expanded, Scopus)

194. Antituberculous therapy-induced fulminant hepatic failure: Successful treatment with liver transplantation and nonstandard antituberculous therapy

Idilman R., Ersoz S., Coban S., Kumbasar Z., Bozkaya H.

LIVER TRANSPLANTATION , cilt.12, sa.9, ss.1427-1430, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

195. A case of systemic lupus erythematosus presenting with protein-losing enteropathy

Türkçapar N., ÖZYÜNCÜ N., ÇINAR K., ENSARİ A., KÜÇÜK N. Ö., İDİLMAN R., et al.

Turkish Journal of Gastroenterology , cilt.17, sa.3, ss.226-230, 2006 (SCI-Expanded)

196. Duration of lamivudine prophylaxis in inactive hepatitis B virus carriers with haemato/oncological malignancies who receive chemotherapy

Idilman R.

GUT , cilt.55, sa.8, ss.1208-1209, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

197. Macro-amylasemia in a patient with selective IgA deficiency and antiphospholipid antibodies

Türkçapar N., ÖZYÜNCÜ N., İDİLMAN R., ENSARİ A., Soylu K., Özden A.

Turkish Journal of Gastroenterology , cilt.17, sa.2, ss.140-143, 2006 (SCI-Expanded) Sürdürülebilir Kalkınma

198. Hepatitis B core antigen expression pattern reflects the response to anti-viral treatment

Uzun Y., Bozkaya H., Erden E., Cinar K., Idilman R., Yurdaydin C., et al.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY , cilt.21, sa.6, ss.977-981, 2006 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

199. Anti-viral prophylaxis in inactive hepatitis B virus carriers with hemato-oncological malignancies who receive chemotherapy

İDİLMAN R.

Minerva Gastroenterologica e Dietologica , cilt.52, sa.1, ss.39-45, 2006 (Scopus) Sürdürülebilir Kalkınma

200. Evaluation of the effect of transplant-related factors and tissue injury on donor-derived hepatocyte and gastrointestinal epithelial cell repopulation following hematopoietic cell transplantation

Idilman R., KUZU I., Erden E., Arat M., Soydan E., Soykan I., et al.

BONE MARROW TRANSPLANTATION , cilt.37, sa.2, ss.199-206, 2006 (SCI-Expanded, Scopus)

201. Long-term prognosis of nonalcoholic fatty liver disease: Is pharmacological therapy actually necessary?

Cinar K., Coban S., Idilman R., Tuzun A., Sarioglu M., Bektas M., et al.

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY , cilt.21, sa.1, ss.169-173, 2006 (SCI-Expanded, Scopus)

202. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver

Arat M., Idilman R., Soydan E., Soykan I., Erden E., Karayalcin S., et al.

CLINICAL TRANSPLANTATION , cilt.19, sa.6, ss.798-803, 2005 (SCI-Expanded, Scopus)

203. Intestinal B cell lymphoma associated with chronic hepatitis C and celiac disease

Coban S., Palabiyikoglu M., ENSARİ A., Idilman R., Koklu S., Yolcu O., et al.

DIGESTIVE DISEASES AND SCIENCES , cilt.50, sa.12, ss.2359-2361, 2005 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

204. Peroxisome proliferator-activated receptor alpha L162V polymorphism in nonalcoholic steatohepatitis and genotype 1 hepatitis C virus-related liver steatosis

Verdi H., Koytak E., Onder O., Cinar K., Idilman R., Erden E., et al.

JOURNAL OF INVESTIGATIVE MEDICINE , cilt.53, sa.7, ss.353-359, 2005 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

205. Trefoil factor expression graft-versus-host disease of in biliary epithelium of the liver after allogeneic hematopoietic cell transplantation

Idilman R., Erden E., Arat M., Soydan E., Erkan O., KUZU I., et al.

TRANSPLANTATION , cilt.80, sa.8, ss.1099-1104, 2005 (SCI-Expanded, Scopus)

206. A new percutaneous approach for the treatment of hydatid cyst of the kidney: Long-term follow-up

Ormeci N., Idilman R., Tuzun A., Erdem H., Palabiyikoglu M.

INTERNATIONAL UROLOGY AND NEPHROLOGY , cilt.37, sa.3, ss.461-464, 2005 (SCI-Expanded, Scopus)

207. Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from Turkish patients with chronic HBV infection

Bozdayi G., Turkyilmaz A., Idilman R., Karatayli E., Rota S., Yurdaydin C., et al.

JOURNAL OF MEDICAL VIROLOGY , cilt.76, sa.4, ss.476-481, 2005 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

208. Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy

Idilman R.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY , cilt.55, sa.6, ss.828-831, 2005 (SCI-Expanded, Scopus)

209. An unusual presentation of helicobacter pylori infection: So-called "Russell body gastritis"

ENSARİ A., Savas B., Heper A., KUZU I., Idilman R.

Virchows Archiv , cilt.446, sa.4, ss.463-466, 2005 (SCI-Expanded, Scopus)

210. Sexual dysfunctions in HCV patients and its correlations with psychological and biological variables

Soykan A., Boztas H., Idilman R., Ozel E. T., Tuzun A., Ozden A., et al.

INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH , cilt.17, sa.2, ss.175-179, 2005 (SCI-Expanded, Scopus)

211. Lamivudine treatment in HBeAg-negative chronic hepatitis B patients with low level viraemia

Bozkaya H., Yurdaydin C., Idilman R., Tuzun A., Cinar K., Erkan O., et al.

ANTIVIRAL THERAPY , cilt.10, sa.2, ss.319-325, 2005 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

212. Recipient-derived hepatocytes in sex-mismatched liver allografts after liver transplantation: Early versus late transplant biopsies

Idilman R., Erden E., KUZU I., Ersoz S., KARASU A. Z., Karayalcin K., et al.

TRANSPLANTATION , cilt.78, sa.11, ss.1647-1652, 2004 (SCI-Expanded, Scopus)

213. Lymphoproliferative disorders in chronic hepatitis C

Idilman R., Colantoni A., De Maria N., Alkan S., Nand S., Van Thiel D.

JOURNAL OF VIRAL HEPATITIS , cilt.11, sa.4, ss.302-309, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

214. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies

Idilman R., Arat M., Soydan E., TÖRÜNER M., Soykan I., Akbulut H., et al.

JOURNAL OF VIRAL HEPATITIS , cilt.11, sa.2, ss.141-147, 2004 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

215. Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation.

Idilman R., Ustun C., Karayaicin S., Aktemel A., Turkyilmaz A., Ozcan M., et al.

Clinical transplantation , cilt.17, sa.5, ss.438-43, 2003 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

216. Hepatic apoptosis and proliferation in male and female rats fed alcohol: role of cytokines

Colantoni A., Idilman R., De Maria N., La Paglia N., Belmonte J., Wezeman F., et al.

ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH , cilt.27, sa.7, ss.1184-1189, 2003 (SCI-Expanded, Scopus)

217. Reversal of iron deficiency anemia in a patient with gastric antral vascular ectasia treated with cyproheptadine

Soykan I., TÖRÜNER M., Idilman R., Ozden A.

JOURNAL OF CLINICAL GASTROENTEROLOGY , cilt.36, sa.2, ss.183-184, 2003 (SCI-Expanded, Scopus)

218. Impaired antibody response rates after high dose short interval hepatitis B virus vaccination of immunosuppressed individuals

Idilman R., Colantoni A., De Maria N., Ustun C., Sam R., Ing T., et al.

HEPATO-GASTROENTEROLOGY , cilt.50, sa.49, ss.217-221, 2003 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

219. A new therapeutic approach for treatment of hydatid cysts of the spleen

Ormeci N., Soykan I., Palabiyikoglu M., Idilman R., Erdem H., Bektas A., et al.

DIGESTIVE DISEASES AND SCIENCES , cilt.47, sa.9, ss.2037-2044, 2002 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

220. Is pain experienced during liver biopsy an important factor?

Soykan I., TÖRÜNER M., Sarioglu M., Idilman R.

JOURNAL OF CLINICAL GASTROENTEROLOGY , cilt.35, sa.1, ss.102-103, 2002 (SCI-Expanded, Scopus)

221. Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C.

De Maria N., Colantoni A., Idilman R., Friedlander L., Harig J., Van Thiel D. H.

Hepato-gastroenterology , cilt.49, sa.45, ss.788-92, 2002 (SCI-Expanded)

222. Estrogen status and response to combination therapy for chronic hepatitis C

De Maria N., Colantoni A., Idilman R., Leone N., Villa E., Van Thiel D.

JOURNAL OF HEPATOLOGY , cilt.36, ss.233, 2002 (SCI-Expanded) Sürdürülebilir Kalkınma

223. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis C

Idilman R., De Maria N., Colantoni A., Nadir A., Van Thiel D.

AMERICAN JOURNAL OF GASTROENTEROLOGY , cilt.97, sa.2, ss.435-439, 2002 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

224. Bronchoalveolar lavage fluid analysis in individuals with chronic hepatitis C

Idilman R., Cetinkaya H., Savas I., Aslan N., SAK S., Bastemir M., et al.

JOURNAL OF MEDICAL VIROLOGY , cilt.66, sa.1, ss.34-39, 2002 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

225. Liver transplantation for fulminant hepatic failure

Van Thiel D., Brems J., Nadir A., Idilman R., Colantoni A., Holt D., et al.

JOURNAL OF GASTROENTEROLOGY , cilt.37, ss.78-81, 2002 (SCI-Expanded, Scopus)

226. Repopulation of liver endothelial cells, but not hepatocytes, by allogeneic hematopoietic cell transplants.

Idilman R., Tukun A., Erdem E., Arat M., TÖRÜNER M., Soykan I., et al.

BLOOD , cilt.98, sa.11, 2001 (SCI-Expanded)

227. B-cell lymphoproliferative and plasma cell disorders in individuals with chronic hepatitis C.

Idilman R., Colantoni A., De Maria N., Alkan S., Nand S., Soykan I., et al.

HEPATOLOGY , cilt.34, sa.4, 2001 (SCI-Expanded) Sürdürülebilir Kalkınma

228. Increased effective immunogenicity to high-dose and short-interval hepatitis B virus vaccination in individuals with chronic hepatitis without cirrhosis

De Maria N., Idilman R., Colantoni A., Van Thiel D.

JOURNAL OF VIRAL HEPATITIS , cilt.8, sa.5, ss.372-376, 2001 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

229. Effect of human immunodeficiency virus on the outcome of hepatitis C virus infection

Idilman R., Colantoni A., De Maria N.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.36, sa.3, ss.225-234, 2001 (SCI-Expanded, Scopus)

230. Evidence of oxidative injury during aging of the liver in a mouse model.

Colantoni A., Idilman R., de Maria N., Duffner L., Van Thiel D., Witte P., et al.

JOURNAL OF THE AMERICAN AGING ASSOCIATION , cilt.24, sa.2, ss.51-57, 2001 (SCI-Expanded, Scopus)

231. The impact of previous HBV infection on the course of chronic hepatitis C

De Maria N., Colantoni A., Friedlander L., Leandro G., Idilman R., Harig J., et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY , cilt.95, sa.12, ss.3529-3536, 2000 (SCI-Expanded, Scopus)

232. Hepatitis B virus vaccination of recipients and donors of allogeneic peripheral blood stem cell transplantation: Risk and benefit ratio of HBV vaccination in recipients.

Idilman R., Ustun C., Akan H., Karayalcin S., Ozcan M., Arslan O., et al.

HEPATOLOGY , cilt.32, sa.4, 2000 (SCI-Expanded) Sürdürülebilir Kalkınma

233. Influence of sex hormonal status on alcohol-induced oxidative injury in male and female rat liver.

Colantoni A., La Paglia N., De Maria N., Emanuele M. A., Emanuele N. V., Idilman R., et al.

Alcoholism, clinical and experimental research , cilt.24, sa.9, ss.1467-73, 2000 (SCI-Expanded, Scopus)

234. Antibody response to hepatitis B virus vaccination in individuals with hepatitis C virus infection

De Maria N., Idilman R., Colantoni A., Harig J., Van Thiel D.

HEPATOLOGY , cilt.32, sa.2, ss.444, 2000 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

235. The response to interferon plus ribavirin re-treatment for chronic hepatitis C in interferon non-responders is not influenced by race

De Maria N., Colantoni A., Idilman R., Harig J., Van Thiel D.

JOURNAL OF HEPATOLOGY , cilt.33, sa.6, ss.1028-1029, 2000 (SCI-Expanded, Scopus)

236. The incidence of Hepatitis G virus in patients with hematological malignancies: The relationship to the number of blood and blood products transfusions

İDİLMAN R., Ustun C., Aslan O., ÖZCAN M. E., Arat M., Bozkaya H., et al.

Turkish Journal of Haematology , cilt.17, sa.2, ss.67-71, 2000 (SCI-Expanded) Sürdürülebilir Kalkınma

237. Immunosuppressive therapy-induced hepatotoxicity in patients with aplastic anemia

Dilek I., İDİLMAN R., Fenkci S., Ustun C., KOÇ H., İLHAN O., et al.

Turkish Journal of Haematology , cilt.17, sa.3, ss.111-117, 2000 (SCI-Expanded)

238. Cirrhosis in Turner's syndrome: Case report and literature review

Idilman R., De Maria N., Colantoni A., Kugelmas M., Van Thiel D.

European Journal of Gastroenterology and Hepatology , cilt.12, sa.6, ss.707-709, 2000 (SCI-Expanded)

239. Flow cytometric evaluation of cell counts in bronchoalveolar lavage fluid of patients with hepatitis C virus: As a predictive marker of idiopathic pulmonary fibrosis

Idilman R., Cetinkaya H., Savas I., Aslan N., Sarioglu M., Bozdayi M., et al.

HEPATOLOGY , cilt.30, sa.4, 1999 (SCI-Expanded) Sürdürülebilir Kalkınma

240. Adoptive immunity transfer in hepatitis B virus carriers with hematological malignancy who undergoing allogeneic hematopoietic stem cell transplantation

Idilman R., Ustun C., Turkyilmaz A., GÜRMAN G., Ozcan M., Karayalcin S., et al.

HEPATOLOGY , cilt.30, sa.4, 1999 (SCI-Expanded) Sürdürülebilir Kalkınma

241. Hematopoietic stem cell transplantation from non-replicative hepatitis B virus carriers is safe

Ustun C., Idilman R., GÜRMAN G., Ozcan M., Akyol G., Akan H., et al.

JOURNAL OF HEPATOLOGY , cilt.31, sa.2, ss.202-209, 1999 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

242. Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced, indolent non-Hodgkin's lymphoma

BEKSAÇ M., Idilman R.

CANCER , cilt.85, sa.1, ss.242-243, 1999 (SCI-Expanded)

243. Is there any correlation between transfusion frequency of blood and blood products and blood-borne hepatitis virus transmission?

Idilman R., Ustun C., Bozkaya H., Bozdayi M., Akan H.

BLOOD , cilt.92, sa.10, 1998 (SCI-Expanded) Sürdürülebilir Kalkınma

244. Which hematopoietic stem cell transplantation type is safe for patients with hepatitis B virus carriers.

Ustun C., Idilman R., Ozcan M., Akan H., Karayalcin S., GÜRMAN G., et al.

HEPATOLOGY , cilt.28, sa.4, 1998 (SCI-Expanded) Sürdürülebilir Kalkınma

245. Bronchoalveolar lavage fluid findings in patients with hepatitis C virus.

Cetinkava H., Idilman R., Savas I., Bastemir M., Karacan O., Sarioglu M., et al.

HEPATOLOGY , cilt.28, sa.4, 1998 (SCI-Expanded) Sürdürülebilir Kalkınma

246. Is there any correlation between transfusion frequency of blood and blood products and hepatitis G virus transmission.

Idilman R., Akan H., Ustun C., Bozkaya H., Bozdayi M., Uzunalimoglu O., et al.

HEPATOLOGY , cilt.28, sa.4, 1998 (SCI-Expanded) Sürdürülebilir Kalkınma

247. Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma

Idilman R., De Maria N., Colantoni A., Van Thiel D.

JOURNAL OF VIRAL HEPATITIS , cilt.5, sa.5, ss.285-299, 1998 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

248. Liver transplantation for chronic viral liver disease.

Colantoni A., Hassanein T., Idilman R., Van Thiel D. H.

Hepato-gastroenterology , cilt.45, sa.23, ss.1357-63, 1998 (SCI-Expanded)

249. Cladribine therapy in chronic lymphoproliferative disorders: Single center experience

BEKSAÇ M., Ilhan O., Uysal A., Koc H., Idilman R., Arat M., et al.

BRITISH JOURNAL OF HAEMATOLOGY , cilt.102, sa.1, ss.244, 1998 (SCI-Expanded)

250. Immunosuppressive drug-induced leukoencephalopathy in patients with liver transplant

Idilman R., De Maria N., Kugelmas M., Colantoni A., Van Thiel D.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.10, sa.5, ss.433-436, 1998 (SCI-Expanded, Scopus)

251. Interferon treatment of HCV positive cirrhotic patients.

Idilman R., Colantoni A., De Maria N., Van Thiel D. H.

Hepato-gastroenterology , cilt.45, sa.20, ss.340-4, 1998 (SCI-Expanded)

252. Fulminant hepatitis in aplastic anemia: hepatitis G or ALG?

Akan H., Konuk N., Fenkci S., Dilek I., Idilman R., Tuncer S.

BONE MARROW TRANSPLANTATION , cilt.21, sa.5, ss.533, 1998 (SCI-Expanded, Scopus)

253. Current and future therapies for HCV infection: what should the end point for treatment be?

Van Thiel D. H., De Maria N., Colantoni A., Idilman R.

Hepato-gastroenterology , cilt.45, sa.20, ss.308-20, 1998 (SCI-Expanded, Scopus)

254. Donor leukocyte infusions for the treatment of leukemia relapse after allogeneic hematopoietic progenitor cell transplantation.

GÜRMAN G., Arslan O., Koc H., Dilek I., Ustun C., Ozcan M., et al.

BLOOD , cilt.90, sa.10, ss.4452, 1997 (SCI-Expanded)

255. Polymerase chain reaction for the detection of HCV-RNA: cryoglobulinaemia as a cause for false negative results.

Colantoni A., De Maria N., Idilman R., Van Thiel D. H.

Italian journal of gastroenterology and hepatology , cilt.29, sa.3, ss.273-4, 1997 (SCI-Expanded)

256. Interferon treatment of cirrhotic patients with chronic hepatitis C

Idilman R., DeMaria N., Colantoni A., Dokmeci A., VanThiel D.

JOURNAL OF VIRAL HEPATITIS , cilt.4, sa.2, ss.81-91, 1997 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

257. Successful medical treatment of epithelioid hemangioendothelioma of liver

Idilman R., Dokmeci A., Beyler A., Bastemir M., Ormeci N., Aras N., et al.

ONCOLOGY , cilt.54, sa.2, ss.171-175, 1997 (SCI-Expanded, Scopus)

258. Hepatic osteodystrophy: A review

Idilman R., DeMaria N., Uzunalimoglu O., VanThiel D.

HEPATO-GASTROENTEROLOGY , cilt.44, sa.14, ss.574-581, 1997 (SCI-Expanded)

259. Protein C, protein S and antithrombin III levels in nephrotic syndrome.

Buyukberber S., Aydogdu I., Buyukberber N., Bektas A., Idilman R., Karatan O., et al.

BLOOD , cilt.88, sa.10, ss.2982, 1996 (SCI-Expanded)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 141

1. Outcomes beyond 10 years in entecavir or tenofovir treated Caucasian chronic hepatitis B patients of the real-life PAGE-B cohort

Papatheodoridis G., Dalekos G., İDİLMAN R., Sypsa V., Buti M., Panero J. L. C., et al.

European-Association-for-the-Study-of-the-Liver Congress, Amsterdam, Hollanda, 7 - 10 Mayıs 2025, cilt.82, (Özet Bildiri)

2. Gut metagenomic profiles predict 90-day hospitalizations despite controlling for diet, demographics & cirrhosis details in a multi-country cohort of patients with cirrhosis

Bajaj J., Nikitina D., Sikaroodi M., Alvares-da-Silva M., Torre A., Suk K. T., et al.

European-Association-for-the-Study-of-the-Liver Congress, Amsterdam, Hollanda, 7 - 10 Mayıs 2025, cilt.82, (Özet Bildiri)

3. WIDE VARIATIONS IN ANTIMICROBIAL GENE CARRIAGE IN PATIENTS WITH CIRRHOSIS AND HEALTHY CONTROLS FROM 7 COUNTRIES WITH 1020 PARTICIPANTS: IMPLICATIONS FOR RESISTANT INFECTIONS

Bajaj J. S., Kupcinskas J., Kreivenaite E., Suk K. T., Sharma S., Lee H. W., et al.

Digestive Disease Week, California, Amerika Birleşik Devletleri, 3 - 06 Mayıs 2025, cilt.169, (Özet Bildiri)

4. MAJOR VARIATIONS IN 90-DAY MORTALITY POST-HOSPITAL DISCHARGE AMONG INPATIENTS WITH CIRRHOSIS: A PROSPECTIVE COHORT STUDY FOR THE CLEARED CONSORTIUM

İDİLMAN R., HAKTANIYAN B., Choudhury A. K., Kamath P., Wong F., Alvares-da-Silva M., et al.

The Liver Meeting, California, Amerika Birleşik Devletleri, 15 - 19 Kasım 2024, (Özet Bildiri)

5. De novo malignancies after liver transplantation: multicenter study a preliminary report

Danis N., Akarsu M., Harputluoglu M., Yilmaz S., Adanir H., Dincer D., et al.

International Congress of the International-Liver-Transplantation-Society (ILTS), Texas, Amerika Birleşik Devletleri, 1 - 04 Mayıs 2024, ss.165-166, (Özet Bildiri)

6. Wide variations in proton pump inhibitor use in hospitalized patients with cirrhosis in a worldwide cohort shows little impact on clinically significant outcomes

Bajaj J., Kamath P. S., Xie Q., Topazian M., Hayes P., Torre A., et al.

European-Association-for-the-Study-of-the-Liver Congress (EASL), Milan, İtalya, 5 - 08 Haziran 2024, (Özet Bildiri)

7. The impact of tumor budding in patients with hepatocelular carcinoma

Duran o. f., GÖKCAN H., KİREMİTCİ S., YILMAZ V., ÇİFTÇİ A., BODAKÇİ E., et al.

EASL congress 2024, 05 Haziran 2024, (Özet Bildiri)

8. C282Y mutation in hemochromatosis: Single center experience

BODAKÇİ E., GÖKCAN H., GÜMÜŞSOY M., GÜVENİR S. T., YILMAZ V., KARAKAYA M. F., et al.

AASLD-TASL hepatology connect meeting 2024, 16 Şubat 2024, (Özet Bildiri)

9. Assesing Hepatic Steatosis by MRI in potential living liver donors

Kuru Öz d., MELEKOĞLU ELLİK Z., GÜRSOY ÇORUH A., GÜMÜŞSOY M., kırımker o. e., GÖKCAN H., et al.

AASLD-TASL hepatology connect meeting 2024, 16 Şubat 2024, (Özet Bildiri)

10. Case series of C282Y mutation in the HFE gene in Turkey: Single-center experience

BODAKÇİ E., GÖKCAN H., güvener t., YILMAZ V., ER R. E., KARAKAYA M. F., et al.

19. Euroasian Hepatogastroenterology and Surgery, 13 Kasım 2023, (Tam Metin Bildiri)

11. Familial NAFLD Cirrhosis Case Series

AKARCA H. T., GÖKCAN H., GÜVENİR S. T., YILMAZ V., İDİLMAN R.

19. Euroasian Hepatogastroenterology and Surgery, 13 Kasım 2023, (Tam Metin Bildiri)

12. Noninvazive fibrosis markers for assesment for liver fibrosis in patients with chronic hepatitis delta

KARAKAYA M. F., KURU ÖZ D., Turan D., DUMAN S., MELEKOĞLU ELLİK Z., GÜMÜŞSOY M., et al.

AASLD 2023 congress, Amerika Birleşik Devletleri, 10 Kasım 2023, (Özet Bildiri)

13. noninvazive fibrosis markers for assesment for liver fibrosis in patients with chronic hepatitis delta

KARAKAYA M. F., KURU ÖZ D., Turan Gökçe D., DUMAN S., Ellik Z. M., GÜMÜŞSOY M., et al.

AASLD 2023 congress, 10 Kasım 2023, (Tam Metin Bildiri)

14. REGIONAL DIFFERENCES IN ACUTE KIDNEY INJURY PREVALENCE, CLINICAL CHARACTERISTICS AND PATIENT OUTCOMES IN A MULTI-NATIONAL CONSORTIUM OF INPATIENTS WITH CIRRHOSIS

Wong F., George J., Hayes P. C., Torre A., Kamath P. S., Xie Q., et al.

Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 10 - 14 Kasım 2023, (Özet Bildiri)

15. NON - INVASIVE FIBROSIS MARKERS FOR ASSESMENT OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS DELTA

BODAKÇİ E., KARAKAYA M. F., KURU ÖZ D., Gokce D., DUMAN S., Ellik Z., et al.

Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 10 - 14 Kasım 2023, cilt.78, (Özet Bildiri)

16. PRIVATE INSURANCE ACCESS IS ASSOCIATED WITH HIGHER LIVER TRANSPLANT LISTING AND TRANSPLANT ACCESS AND LOWER MORTALITY COMPARED TO NATIONAL INSURANCES IN A LARGE MULTINATIONAL COHORT OF INPATIENTS WITH CIRRHOSIS

Bajaj J. S., Wong F., Xie Q., Kamath P. S., Topazian M., Hayes P. C., et al.

Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 10 - 14 Kasım 2023, (Özet Bildiri)

17. GLOBAL PREVALENCE OF INFECTIONS AND IMPACT OF REGIONAL VARIATIONS ON OUTCOMES: MULTI-NATIONAL CONSORTIUM OF CIRRHOSIS STUDY

Xie Q., Cao Z., Choudhury A. K., Kamath P. S., Topazian M., Hayes P. C., et al.

Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 10 - 14 Kasım 2023, (Özet Bildiri)

18. ALCOHOL-RELATED ETIOLOGY IS AN INDEPENDENT PREDICTOR OF INPATIENT MORTALITY IN PATIENTS WITH CIRRHOSIS IN A PROSPECTIVE GLOBAL CONSORTIUM

Choudhury A. K., Wong F., Xie Q., Kamath P. S., Topazian M., Hayes P. C., et al.

Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 10 - 14 Kasım 2023, (Özet Bildiri)

19. A STUDY OF ACUTE LIVER INJURY ASSOCIATED WITH ORNIDAZOLE: ANALYSIS OF 82 CASES IN TURKIYE

TURAN İ., DURMAZER E. N., Vatansever S., Caliskan A. R., Harputluoglu M., Efe C., et al.

Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), Massachusetts, Amerika Birleşik Devletleri, 10 - 14 Kasım 2023, (Özet Bildiri)

20. development of Metabolic Disorders in Transplant Recepients

Erdemir G., GÖKCAN H., Gürsoy Çoruh A., GÜLPINAR B., MELEKOĞLU ELLİK Z., GÜMÜŞSOY M., et al.

EASL Congress 21-24 June 2023, Avusturya, 21 - 24 Haziran 2023, cilt.78, ss.477-478, (Tam Metin Bildiri)

21. development of Metabolik disorders in Liver transplant recepients

Erdemir G., GÖKCAN H., İDİLMAN R.

The 2023 International congress of ILTS ELITA and LICAGE, 03 Mayıs 2023, (Tam Metin Bildiri)

22. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.

DUMAN S., KURU ÖZ D., GÜMÜŞSOY M., KİREMİTCİ S., GÖKCAN H., ÖZERCAN A. M., et al.

AASLD-TASL hepatology connect meeting, 28 - 29 Nisan 2023, (Tam Metin Bildiri)

23. Development of Metabolic Disorders in Transplant Recepients

erdemir g., GÖKCAN H., GÜRSOY ÇORUH A., GÜMÜŞSOY M., DUMAN S., İDİLMAN R.

AASLD-TASL hepatology connect meeting, 28 - 29 Nisan 2023, (Tam Metin Bildiri)

24. Natural Disease outcome in patients with NAFLDÇ a study with paired liver biopsies

GÜMÜŞSOY M., TURAN D., ekelik m., KİREMİTCİ S., DUMAN S., GÜVENİR S. T., et al.

AASLD-TASL hepatology connect meeting, 28 Nisan 2023, (Tam Metin Bildiri)

25. A case of AFP producing cholangiocarcinoma

BODAKÇİ E., GÜMÜŞSOY M., GÜVENİR S. T., KARAKAYA F., GÖKCAN H., İDİLMAN R.

AASLD-TASL hepatology connect meeting, 28 - 29 Nisan 2023, (Tam Metin Bildiri)

26. effect of prognostic tests on disease outcome of alcohol-related liver disease

zengin b. a., GÜMÜŞSOY M., DUMAN S., BODAKÇİ E., ÖZERCAN A. M., ER R. E., et al.

AASLD-TASL hepatology connect meeting, 28 Nisan 2023, (Tam Metin Bildiri)

27. İdentification of risk factors for alcohol relapse in liver transplant patients with alcohol- related liver disease.

TURAN D., GÜNŞAR F., harputluoğlu m., KABAÇAM G., GÖKCAN H., AKARSU M., et al.

EASL Congress 21-24 June 2023, 21 Nisan 2023, (Tam Metin Bildiri)

28. A Combination Of Non-Invasive Tests In Detection Of NAFLD-Related Advanced Fibrosis Is Not Superior To MRE Alone

Duman S., Gümüşsoy M., Kuru D., Kiremitci S., Gökcan H., Bodakçı E., et al.

39. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber, Bochum, Almanya, 27 - 28 Ocak 2023, cilt.61, ss.30, (Özet Bildiri)

29. MEFIB AND MAST SCORES ASSESSMENT OF INCIDENT LIVER-RELATED OUTCOMES IN NONALCOHOLIC FATTY LIVER DISEASE: AN INDIVIDUAL PATIENT META-ANALYSIS

Noureddin N., Ajmera V., Bergstrom J., Huang D., Siddiqi H., Majzoub A. M., et al.

American Association for the Study of Liver Diseases, The Liver Meeting (AASLD 2022), Amerika Birleşik Devletleri, 4 - 08 Kasım 2022, (Özet Bildiri)

30. Alkol Dışı Yağlı Karaciğer Hastalığı Doğal Seyri: Ardışık İkili Karaciğer Biyopsilerinin Karşılaştırılması

GÜMÜŞSOY M., TURAN D., EKELİK M., KİREMİTCİ S., BODAKÇİ E., DUMAN S., et al.

39. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Türkiye, 22 Kasım 2022, (Özet Bildiri)

31. Effect of prognostic noninvasive tests on disease outcome of alcohol related liver disease

zengin a., GÜMÜŞSOY M., DUMAN S., BODAKÇİ E., GÜVENİR S. T., MELEKOĞLU ELLİK Z., et al.

aasld 2022, 04 Kasım 2022, (Özet Bildiri)

32. Natural disease Outcome in patients with NAFLD: A study with paired liver biopsy

GÜMÜŞSOY M., Turan Gökçe D., KİREMİTCİ S., BODAKÇİ E., DUMAN S., MELEKOĞLU ELLİK Z., et al.

aasld 2022, 04 Kasım 2022, (Özet Bildiri)

33. Metabolic Syndrome in liver Transplant recipient

KARA G., GÖKCAN H., İDİLMAN R.

AASLD 2022, 4 - 08 Kasım 2022, (Özet Bildiri)

34. Real Life Efficacy and tolerability of Tenofovir alafenamide fumarate in patients with hepatitis B virus related cirrhosis

YAPALI S., GÖKCAN H., DURAK S., MELEKOĞLU ELLİK Z., ADANIR H., GÜNDÜZ F. F., et al.

ınternational Liver congress ILC 2022 (EASL), 22 - 26 Haziran 2022, (Özet Bildiri)

35. Trends and causes of etiology in adult liver transplant patients: multicenter study

AKARSU M., Harputluoğlu M., YILMAZ S., GENÇDAL G., AKYILDIZ M., DİNÇER D., et al.

ınternational Liver congress ILC 2022 (EASL), 22 - 26 Haziran 2022, (Özet Bildiri)

36. Preliminary Results of The effectiveness and safety of Tenofovir alafenamide Fumarate Prophylaxis in HBV individuals, who received Chemo/Immunsupression therapy

GÜNDÜZ F. F., DURAK S., ÜNSAL Y., DEMİR M., MELEKOĞLU ELLİK Z., YILDIRIM A. E., et al.

ınternational Liver congress ILC 2022 (EASL), 22 Haziran 2022, (Özet Bildiri)

37. Effectiveness of MRI methods in the asssement of hepatic steatosis in living liver donors

KURU ÖZ D., MELEKOĞLU ELLİK Z., GÜRSOY ÇORUH A., GÜMÜŞSOY M., DUMANLI S., ER R. E., et al.

ınternational Liver congress ILC 2022 (EASL), 22 Haziran 2022, (Özet Bildiri)

38. Real Life Efficacy and tolerability of Tenofovir alafenamide fumarate in liver transplant recipients: A multicenter study

YAPALI S., GÖKCAN H., MELEKOĞLU ELLİK Z., GÖKÇEN P., ADANIR H., DURAK S., et al.

ILTS 2022, 04 Mayıs 2022, (Özet Bildiri)

39. Biliary complications and management in liver transplant recipients with duct to duct anastomosis: A single center experience

KARAKAYA M. F., ÇINAR K., ER R. E., KIRIMKER E. O., BALCI D., ÖZERCAN A. M., et al.

AASLD-TASL Digital Hepatology Meeting, 14 Ocak 2022, (Özet Bildiri)

40. The Effect of Clinicopathologic findings of Hepatosellüler carcinoma on posttransplant survival: A multicenter kohort from TASL Liver Transplantation special İnterest group

AKYILDIZ M., GENÇDAL G., İNCE V., Harputluoğlu M., ZEYTÜNLÜ M., KILIÇ M., et al.

AASLD-TASL digital Hepatology Connect, 14 - 16 Ocak 2022, (Tam Metin Bildiri)

41. Real Life Efficacy and tolerability of Tenofovir alafenamide fumarate in patiernts with hepatitis B virus related cirrhosis

YAPALI S., GÖKCAN H., DURAK S., MELEKOĞLU ELLİK Z., VATANSEVER S., ADANIR H., et al.

AASLD-TASL digital Hepatology Connect, 14 Nisan 2022, (Özet Bildiri)

42. Trends and changes of etiology in adult liver transplant patients: mulitcenter study

AKARSU M., Harputluoğlu M., YILMAZ S., AKYILDIZ M., GENÇDAL G., polat k. y., et al.

AASLD-TASL digital Hepatology Connect, 14 Ocak 2022, (Tam Metin Bildiri)

43. Efficacy and Safety of Tenofovir alafenamide in hepatitis B virus infected patients with chronic hemodialsis and renal transplantation: a preliminary result

ADANIR H., ÖZER ETİK D., YILDIRIM A. E., YAPALI S., ARI D., GÖKCAN H., et al.

AASLD-TASL digital Hepatology Connect, 14 Ocak 2022, (Özet Bildiri)

44. Bliary Complications and Management in Liver Transplant Patients with Duct to Duct Anastomotis: Single Center Experience

KARAKAYA M. F., ÇINAR K., ER R. E., KIRIMKER E. O., BALCI D., ÖZERCAN A. M., et al.

AASLD-TASL digital Hepatology Connect, 14 Ocak 2022, (Özet Bildiri)

45. Development of Metabolic Disorders İn Liver Transplant Patients

KARA G., GÖKCAN H., GÜMÜŞSOY M., DUMAN S., İDİLMAN R.

AASLD-TASL digital Hepatology Connect, 14 Ocak 2022, (Özet Bildiri)

46. Presentation and outcome of autoimmune hepatitis during pregnancy

örmeci a., DUMAN S., İSTEMİHAN Z., GÖKCAN H., ÇAVUŞ B., ARSLAN K., et al.

AASLD-TASL digital Hepatology Connect, 14 Ocak 2022, (Özet Bildiri)

47. ’Duct to Duct Anastomozlu’ Karaciğer Transplantasyon Hastalarında Biliyer Komplikasyonlar ve Yönetimi: Tek Merkez Deneyimi

KARAKAYA M. F., ÇINAR K., ER R. E., KIRIMKER E. O., BALCI D., ÖZERCAN A. M., et al.

38. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Türkiye, 16 Kasım 2021, (Özet Bildiri)

48. Karaciğer Donörlerinin Preoperatif Yağlanma Değerlendirilmesinde MRG Yöntemlerinin Etkinliği

Kuru Öz D., Melekoğlu Ellik Z., Gürsoy Çoruh A., Adıgüzel M., Gümüşsoy M., Duman S., et al.

38. Ulusal Gastroenteroloji Haftası, 2021, Antalya, Türkiye, 16 Ekim - 21 Kasım 2021, ss.160-161, (Özet Bildiri)

49. association. between non-alcoholic fatty liver disease and extrahepatic malignancy

GÜMÜŞSOY M., İDİLMAN R., GÖKCAN H., BODAKÇİ E., özercan m., ER R. E., et al.

EASL gongress 2021, 23 Haziran 2021, (Özet Bildiri)

50. Non-alcoholic fatty liver disease and extrahepatic malignancy

Gümüşsoy M., Turan Gökçe D., Ulaş B. B., Koç Ö., Karataş G., Bodakçı E., et al.

AASLD-TASL digital Hepatology Connect, 15 Ocak 2021, (Tam Metin Bildiri)

51. The analysis of liver transplant patients with COVİD-19 infection: a national cohort

KABAÇAM G., TURAN İ., KIYICI M., MELEKOĞLU ELLİK Z., dolu S., Dayangaç M., et al.

AASLD-TASL digital Hepatology Connect, İstanbul, Türkiye, 15 - 16 Ocak 2021, cilt.2, ss.24-25, (Özet Bildiri)

52. AMAP RISK SCORE PREDICTS HEPATOCELLULAR CARCINOMA DEVELOPMENT IN CHRONIC HEPATITIS PATIENTS: AN INTERNATIONAL COHORT COLLABORATION

Fan R., Papatheodoridis G., Sun J., Innes H., Toyoda H., Xie Q., et al.

Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72, (Özet Bildiri) Sürdürülebilir Kalkınma

53. MAGNETIC RESONANCE ELASTOGRAPHY AND TRANSIENT ELASTOGRAPGHY TO ASSESS HEPATIC STETAOSIS AND LIVER FIBROSIS IN THE LIVER TRANSPLANT SETTING

Ellik Z., İDİLMAN İ. S., Kartal A. C., Balaban Y. H., KARÇAALTINCABA M., İDİLMAN R.

Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72, (Özet Bildiri)

54. Diagnostic accuracy of liver stiffness measurement by fibroscan in liver transplant recipients

MELEKOĞLU ELLİK Z., ÇALIŞKAN A., DUMAN S., GÜMÜŞSOY M., ÖZERCAN A. M., ER R. E., et al.

EASL: The Digital International Liver Congress, 27 - 29 Ağustos 2020, cilt.73, ss.528, (Özet Bildiri)

55. Outcomes following deceased and live donor livertransplantation for the indication of acute liver failure: amulticenter experience

TURAN İ., ALADAĞ M., HARPUTLUOĞLU M. M. M., YILMAZ S., GENÇDAL G., POLAT K. Y., et al.

The Digital International Liver Congress (EASL) 2020, 27 - 29 Ağustos 2020, cilt.73, ss.227, (Tam Metin Bildiri)

56. ASSOCIATION BETWEEN NON-ALCOHOLOIC FATTY LIVER DISEASE AND SUBCLINICAL ATHEROSCLEROSIS AND MYOCARDIAL DYSFUNCTION USING MULTIMODALITY IMAGING

ULAŞ B. B., ÖZYÜNCÜ N., ÇALIŞKAN KARTAL A., PEKER E., TURAN GÖKÇE D., GÜMÜŞSOY M., et al.

ANNUAL MEETING OF AASLD / LIVER MEETING, 8 - 12 Kasım 2019, (Tam Metin Bildiri)

57. SIMILAR RISK OF HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT DURING LONG-TERM ENTECAVIR (ETV) OR TENOFOVIR DISOPROXIL FUMARATE (TDF) THERAPY IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS

Papatheodoridis G. V., Dalekos G. N., Yurdaydin C., Sypsa V., van Boemmel F., Buti M., et al.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri) Sürdürülebilir Kalkınma

58. ASSOCIATION BETWEEN NON-ALCOHOLIC FATTY LIVER DISEASE AND SUBCLINICAL ATHEROSCLEROSIS AND MYOCARDIAL DYSFUNCTION USING MULTIMODALITY IMAGING

Ulas B. B., ÖZYÜNCÜ N., Kartal A. C., PEKER E., Gokce D., Gumussoy M., et al.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri)

59. TREATMENT DISCONTINUATION IN HBEAG-NEGATIVE CHRONIC HEPATIT B IS A VIABLE OPTION IN NON-CIRRHOTIC GENOTYPE D CHRONIC HEPATITIS B PATIENTS

ŞAH ÜNAL F. T., Keskin O., Yurdcu E., Yilmaz Y., KARAKAYA M. F., Kartal A., et al.

60. NATURAL HISTORY OF INACTIVE HBsAg CARRIERS: A 10-YEAR PROSPECTIVE FOLLOW-UP STUDY

Yurdaydin C., Keskin O., Yurdcu E., Yakut M., Seven G., Kabacam G., et al.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri)

61. TÜRKİYE’DE HEPATİT C ELİMİNASYONU YOL HARİTASI ÖNERİLERİ VE ÇALIŞTAY RAPORU

AKARCA U. S., AYGEN B., bodur h., GÜNER H. R., İDİLMAN R., KAYMAKOĞLU S., et al.

XI.Ulusal Viral Hepatit Simpozyumu, Türkiye, 14 - 16 Haziran 2019, (Özet Bildiri) Sürdürülebilir Kalkınma

62. ETIOLOGY OF CIRRHOSIS CHANGING TRENDS OVER THE YEARS: A SINGLE-CENTER TURKISH EXPERIENCE

İDİLMAN R., ÇALIŞKAN KARTAL A., AYDOĞAN M., KARAKAYA M. F., KALKAN Ç., ÖNEM S., et al.

DDW 2019, 19 - 21 Mayıs 2019, (Özet Bildiri)

63. 10 YILLIK PROSPEKTİF ÇALIŞMADA DÜŞÜK VİRAL YÜKLÜ HBV TAŞIYICILARI REAKTİVASYONDAN ZİYADE HBSAG KAYBETMEYE YATKINDIR.

KESKİN O., YAKUT M., YURDCU E., KALKAN Ç., AGAYEVA S., YILMAZ Y., et al.

12. ULUSAL HEPATOLOJİİ KONGRESİ, Antalya, Türkiye, 1 - 05 Mayıs 2019, (Özet Bildiri)

64. Plasma metabolomic changes modulate the impact of Middle Eastern versus Western Diet in an international cirrhosis cohort

Cox I. J., İDİLMAN R., Fagan A., Turan D., Ajayi L., Karakaya F., et al.

International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Avusturya, 10 - 14 Nisan 2019, cilt.70, (Özet Bildiri)

65. Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients

Papatheodoridis G., Dalekos G., Yurdaydin C., Sypsa V., van Bommel F., Buti M., et al.

International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Avusturya, 10 - 14 Nisan 2019, cilt.70, (Özet Bildiri) Sürdürülebilir Kalkınma

66. Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study

Hardtke S., Wedemeyer H., Caruntu F. A., Curescu M., Kendal Y., AKARCA U. S., et al.

International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Avusturya, 10 - 14 Nisan 2019, cilt.70, (Özet Bildiri)

67. Comparison of the efficacy of short term and long term nucleos(t)ide analog treatment in chronic delta hepatitis

YURTAYDIN S. C., KESKİN O., KARAKAYA M. F., YILMAZ Y., ÇALIŞKAN KARTAL A., MELEKOĞLU ELLİK Z., et al.

35. ULUSAL GASTROENTEROLOJİ HAFTASI, Antalya, Türkiye, 21 Kasım 2018, (Özet Bildiri)

68. Nonnvasve Fbross Scores Are Not Useful for Predcton of Response to Treatment n Chronc Delta Hepatts

KESKİN O., YURDCU E., KALKAN Ç., ÇALIŞKAN KARTAL A., ELLİK Z., BOZDAYI A. M., et al.

AASLD LIVER MEETING 2018, San-Francisco, Kostarika, 9 - 13 Kasım 2018, (Özet Bildiri)

69. Predicition and need for surveillance of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir or tenofovir disoproxil fumarate therapı in Caucasian chronic hepatitis B patients of the PAGE-B Cohort.

Papatheodoridis G., Dalekos G., YURTAYDIN S. C., Sypsa V., Bommel V., Buti m., et al.

AASLD, 9 - 13 Kasım 2018, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

70. ALT Levels and Risk of Hepatocellular Carcinoma (HCC) in Caucasian Chronic Hepatitis B (CHB) Patients Under Long-Term Therapy with Entecavir (ETV) or Tenofovir Disoproxil Fumarate (TDF)

Papatheodoridis G. V., Dalekos G. N., Yurdaydin C., Sypsa V., van Bommel F., Buti M., et al.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Kostarika, 9 - 13 Kasım 2018, cilt.68, (Özet Bildiri) Sürdürülebilir Kalkınma

71. Prediction and Need for Surveillance of Hepatocellular Carcinoma (HCC) Development after the First 5 Years of Entecavir (ETV) or Tenofovir Disoproxil Fumarate (TDF) Therapy in Caucasian Chronic Hepatitis B (CHB) Patients of the PAGE-B Cohort

Papatheodoridis G. V., Dalekos G. N., Yurdaydin C., Sypsa V., van Bommel F., Buti M., et al.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Kostarika, 9 - 13 Kasım 2018, cilt.68, (Özet Bildiri) Sürdürülebilir Kalkınma

72. Noninvasive Fibrosis Scores Are Not Useful for Prediction of Response to Treatment in Chronic Delta Hepatitis

Keskin O., Yurdcu E., Kalkan C., Kartal A., Ellik Z., Bozdayi M., et al.

Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Kostarika, 9 - 13 Kasım 2018, cilt.68, (Özet Bildiri) Sürdürülebilir Kalkınma

73. Patient Selection and Preparation for Liver Transplantation

İDİLMAN R.

APASL Single Topic Non-Responders, 27 - 29 Eylül 2018, (Tam Metin Bildiri)

74. Real world data on safety and efficacy of Ledipasvir Sofosbuvir ± RBV, Ombitasvir / Paritaprevir / Ritonavir ± Dasabuvir ± RBV combination therapy for chronic hepatitis C. A Turkey experience.

DEMİR M., DANIŞ N., KANİ H. T., YILDIRIM A. E., BALKAN A., DEĞERTEKİN M. B., et al.

APASL Single Topic Conference, İstanbul, Türkiye, 27 - 29 Eylül 2018, (Özet Bildiri) Sürdürülebilir Kalkınma

75. HEPATİT C ENFEKSİYONUNA BAĞLI DEKOMPANZE SİROZ HASTALARINDA VE KRONİK HEPATİT C ENFEKSİYONU NEDENİYLE KARACİĞER NAKLİ OLANLARDA LEDİPASVİR/SOFOSBUVİR TEDAVİSİNİN ETKİLİLİĞİ: TÜRKİYE ERKEN ERİŞİM PROGRAMI SONUÇLARI

İDİLMAN R., DEMİR M., ALADAĞ M., KAYMAKOĞLU S., EROL C., ÇAVUŞ B., et al.

34. ULUSAL GASTROENTEROLOJİ HAFTASI, Türkiye, 1 - 06 Aralık 2017 Sürdürülebilir Kalkınma

76. OTOIMMÜN KARACIĞER HASTALIKLARINA EŞLIK EDENEKSTRAHEPATIK OTOIMMÜN HASTALIKLAR VE HASTALIK SEYRI ÜZERINE ETKISI

KARAKAYA M. F., ÖZTEKİN Ş., ÖZTÜRK UÇAR Y., KALKAN Ç., ELHAN A. H., SOYKAN A. İ., et al.

UGH 2017, Türkiye, 1 - 06 Aralık 2017, (Özet Bildiri)

77. New therapies for HCV

İDİLMAN R.

16th International Euroasian Congress of Gastroenterology and Surgery, 27 - 30 Nisan 2017, (Özet Bildiri)

78. Efficacy of ledipasvir and sofosbuvir with/without ribavirin for treatment of chronic hepatitis C patients with advanced liver disease results of a multicenter turkish early access program

İDİLMAN R., demir m., ALADAĞ M., KAYMAKOĞLU S., EROL C., cavus b., et al.

Viral Hepatitis, 3 - 04 Mart 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

79. EFFICIACY OF LEDİPASVİR AND SOFOSBUVİR WİTH/WİTHOUT TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH ADVANCED LIVER DISEASE RESULT OF A MULTICENTER TURKISH EARLY ACCES PROGRAM

İDİLMAN R., DEMİR M., ALADAĞ M., KAYMAKOĞLU S., EROL C., ÇAVUŞ B., et al.

VIRAL HEPATITIS (ENDORSED BY AASLD), 3 - 04 Mart 2017 Sürdürülebilir Kalkınma

80. Efficacy of ledipasvir and sofosbuvir with/without ribavirin for treatmentof hepatitis C patients Results of a multicenter Turkish Early Access Program

İDİLMAN R., DEMİR M., ALADAĞ M., KAYMAKOĞLU S., CİHAN E., ÇAVUŞ B., et al.

Viral Hepatitis, 3 - 04 Mart 2017, (Özet Bildiri) Sürdürülebilir Kalkınma